此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

RECAP 2 裸盖菇素的行为影响

2026年11月3日 更新者:University of Wisconsin, Madison

经验、意识意识和可塑性在裸盖菇素行为影响中的作用 - 后续研究(RECAP 2 研究)

The goal of this clinical trial is to learn about the role that inducing neuroplasticity (the brain's ability to adapt and change) plays in the behavioral effects of psilocybin in people who have experienced a mild decline in emotional wellbeing.

Researchers will compare different doses of psilocybin combined with midazolam or placebo to see what dose induces increased wellbeing.

Participants will:

  • Receive one of four possible combinations of medications
  • Undergo an MRI
  • Complete questionnaires
  • Undergo transcranial magnetic stimulation (TMS) and EEG
  • Volunteer for an open-label follow-up phase of study

研究概览

详细说明

The purpose of this study is to investigate the role that inducing neuroplasticity plays in the behavioral effects of psilocybin in people with modest decrements in emotional wellbeing.

研究类型

介入性

注册 (估计的)

60

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Wisconsin
      • Madison、Wisconsin、美国、53792
        • 招聘中
        • UW School of Medicine and Public Health

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 65年 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age 18 to 65 years at screening, of any identified gender and racial/ethnic group
  • Physically healthy; does not meet criteria for an exclusionary medical condition
  • English-speaking (able to provide consent and complete questionnaires)
  • Modest decrement in self-reported wellbeing without the presence of a DSM-5 Axis I mood or anxiety disorder
  • Able to undergo magnetic resonance imaging (MRI) and transcranial magnetic stimulation (TMS)

Exclusion Criteria:

  • Exclusionary DSM-5 psychiatric diagnosis and/or active suicidal ideation
  • Exclusionary medical conditions
  • Clinically significant safety lab abnormalities (i.e., Complete Blood Count with Differential, Comprehensive Metabolic Panel, and urinalysis)
  • Clinically significant electrocardiogram (ECG)
  • Use of psychotropic or CNS-altering medications within 3 months of screening
  • Hypertension or tachycardia

Participants invited to participate in the 28-day open label follow-up phase will:

  1. Fully complete all activities associated with the randomized phase, including the virtual Day 84 assessment, before being approached about participation in the open label phase.

  2. Participants who meet stopping criteria during the randomized phase are not eligible to enroll in the open label phase.

  3. Participants who withdraw from the randomized phase are not eligible to enroll in the open label phase.

  4. Enrollment into the open label phase must occur in the following sequence:

    1. participants who have fully completed the randomized phase are screened for eligibility;
    2. eligible participants meet with the study team and provide informed consent for the open label phase;
    3. baseline eligibility is reassessed to confirm that participation in the open label phase remains appropriate and safe.

The Principal Investigator may decline or defer open-label enrollment when unresolved concerns make participation unsafe or scientifically inappropriate.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:基础科学
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
实验性的:Group 1: Psilocybin and intravenous (IV) midazolam

Psilocybin (25 mg) + IV midazolam

25mg of psilocybin

其他名称:
  • 裸盖菇素
  • 赛洛西宾

1mg of psilocybin

其他名称:
  • 裸盖菇素
  • 赛洛西宾

The goal of the midazolam dosing regimen is to induce amnesia of the psychedelic experience without inducing over-sedation during the dosing session.

实验性的:Group 2: Psilocybin and IV saline

Psilocybin (25 mg) + IV saline (placebo for midazolam)

25mg of psilocybin

其他名称:
  • 裸盖菇素
  • 赛洛西宾

1mg of psilocybin

其他名称:
  • 裸盖菇素
  • 赛洛西宾

Saline will be administered as a placebo for midazolam

实验性的:Group 3: Psilocybin and IV midazolam

Psilocybin (1 mg/control) + IV midazolam

25mg of psilocybin

其他名称:
  • 裸盖菇素
  • 赛洛西宾

1mg of psilocybin

其他名称:
  • 裸盖菇素
  • 赛洛西宾

The goal of the midazolam dosing regimen is to induce amnesia of the psychedelic experience without inducing over-sedation during the dosing session.

实验性的:Group 4: Psilocybin and IV saline

Psilocybin (1 mg/control) + IV saline

25mg of psilocybin

其他名称:
  • 裸盖菇素
  • 赛洛西宾

1mg of psilocybin

其他名称:
  • 裸盖菇素
  • 赛洛西宾

Saline will be administered as a placebo for midazolam

实验性的:Exploratory Open Label Follow-Up Phase

Psilocybin (25 mg)

25mg of psilocybin

其他名称:
  • 裸盖菇素
  • 赛洛西宾

1mg of psilocybin

其他名称:
  • 裸盖菇素
  • 赛洛西宾

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in Warwick-Edinburgh Mental wellbeing Scale (WEMWBS)
大体时间:Baseline to 7 days post-dose

WEMWBS is a 14-item questionnaire in which participants describe their experience of each item. It is scored on a 5-point Likert scale, possible range of 14-70 where higher scores indicate higher levels of wellbeing.

Baseline to 7 days post-dose
Change in Brief Experiential Avoidance Questionnaire (BEAQ)
大体时间:Baseline to 7 days post-dose

The BEAQ is a 15-item questionnaire assessing participants agreement with wellbeing statements. It is scored on a 6-point Likert scale, ranging from 15-90 with higher scores indicating a greater tendency towards experiential avoidance

Baseline to 7 days post-dose
Change in Probabilistic Reversal Learning (PRL)
大体时间:Baseline to 7 days post-dose

Participants are presented with two stimuli or options and learn which one is more likely to be associated with a reward based on feedback after each trial. After a certain number of trials, the reward contingencies are reversed, meaning the previously advantageous option becomes less likely to be rewarded, and vice versa. The task assesses how quickly and effectively individuals can adapt to these changes in reward contingencies. Researchers analyze various performance metrics, such as the speed of reversal, the number of errors, and the patterns of choices (e.g., win-stay, lose-shift).

Baseline to 7 days post-dose
Change in transcranial magnetic stimulation evoked potential (TEP) amplitude
大体时间:Baseline to 7 days post-dose

TEP measures neural excitability in the stimulated region of the brain.

Baseline to 7 days post-dose

次要结果测量

结果测量
措施说明
大体时间
Change in WEMWBS
大体时间:Baseline to 28 days post-dose

WEMWBS is a 14-item questionnaire in which participants describe their experience of each item. It is scored on a 5-point Likert scale, possible range of 14-70 where higher scores indicate higher levels of wellbeing.

Baseline to 28 days post-dose
Change in BEAQ
大体时间:Baseline to 28 days post-dose

The BEAQ is a 15-item questionnaire assessing participants agreement with wellbeing statements. It is scored on a 6-point Likert scale, ranging from 15-90 with higher scores indicating a greater tendency towards experiential avoidance

Baseline to 28 days post-dose
Change in PRL
大体时间:Baseline to 28 days post-dose

Participants are presented with two stimuli or options and learn which one is more likely to be associated with a reward based on feedback after each trial. After a certain number of trials, the reward contingencies are reversed, meaning the previously advantageous option becomes less likely to be rewarded, and vice versa. The task assesses how quickly and effectively individuals can adapt to these changes in reward contingencies. Researchers analyze various performance metrics, such as the speed of reversal, the number of errors, and the patterns of choices (e.g., win-stay, lose-shift).

Baseline to 28 days post-dose
Change in TEP amplitude
大体时间:Baseline to 28 days post-dose

TEP measures neural excitability in the stimulated region of the brain.

Baseline to 28 days post-dose
Altered States of Consciousness (ASC) questionnaire
大体时间:Dosing 1 day

Participants will complete a selection of several questions from the ASC questionnaire that strongly associate positively or negatively with later antidepressant effect of psilocybin in patients with treatment resistant depression or capture classic features of the psychedelic experience. During the dosing session, investigator will repeatedly ask selected items from the ASC scale to get a "real time" measure of what the participants are experiencing. Each of these items will be scored separately. Higher score are indicative of a more intense psychedelic experience.

Dosing 1 day
Emotional Breakthrough Inventory (EBI)
大体时间:Dosing 1 day

The EBI is a 6-item scale that assesses the presence and severity of emotionally challenging/distressing experiences that occur during a psychedelic experience. Participants rate to what extent the statements apply to their experience by marking a single line across each scale. Scale ranges from not at all to very much so. Higher scores (more slashes toward the 'very much so' end) on the scale have been associated with enhanced well-being following psychedelic use

Dosing 1 day
Psychological Insight Questionnaire (PIQ)
大体时间:Dosing 1 day

The PIQ is a 23-item instrument designed to query self-perceived attainment of insight during a psychedelic medicine session. Items are rated on a 6-point Likert scale, 0 = no not at all and 5 = extremely. Possible scares range from 0-115, with higher scores indicating greater insight.

Dosing 1 day

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Charles Raison, MD、University of Wisconsin, Madison

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年8月7日

初级完成 (估计的)

2027年12月1日

研究完成 (估计的)

2027年12月1日

研究注册日期

首次提交

2024年11月14日

首先提交符合 QC 标准的

2024年11月15日

首次发布 (实际的)

2024年11月18日

研究记录更新

最后更新发布 (实际的)

2026年11月6日

上次提交的符合 QC 标准的更新

2026年11月3日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

关键字

其他研究编号

  • 2024-0852
  • A538900 (其他标识符:UW- Madison)
  • SMPH/PSYCHIATRY/PSYCHIATRY (其他标识符:UW- Madison)
  • Protocol Version 9/30/2026 (其他标识符:UW- Madison)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅